Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL®(bempedoic acid) Tablets and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results